Skip to content

Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors

Smoking Cessation and Alcohol Use Among Cancer Survivors: Investigating the Efficacy of a Mindfulness-Based Intervention

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07447635
Enrollment
600
Registered
2026-03-03
Start date
2026-05-15
Completion date
2029-12-01
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use, Smoking Cessation

Keywords

Mindfulness-based intervention, Cancer survivors, Smoking cessation, Alcohol use

Brief summary

This study will examine the efficacy of Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA) compared to standard care among cancer survivors who smoke cigarettes and engage in at-risk alcohol use. Investigators will evaluate implementation outcomes through structured stakeholder interviews across medical centers, cancer-focused organizations, and community-based programs in Florida, and will conduct a cost-assessment and an incremental cost-effectiveness analysis of the two conditions.

Detailed description

The primary aim of this study is to test the efficacy of MBRP-SA compared with standard care among cancer survivors, explore potential moderators, mechanisms, and predictors of treatment effects, and evaluate implementation outcomes to guide future adoption of MBRP-SA.

Interventions

BEHAVIORALMindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA)

MBRP-SA is a nine-week, group-based mindfulness program designed to help cancer survivors quit smoking and reduce heavy alcohol use by targeting craving, stress, and habitual behavior patterns. Participants will also receive 10 weeks of nicotine replacement therapy.

BEHAVIORALQuitline Support

Participants will be connected to the Florida Tobacco Quitline, which provides standard evidence-based smoking cessation support, including phone-based counseling, web-based resources, and access to text-messaging programs. The Quitline also offers up to a four-week supply of nicotine replacement therapy (patches, gum, or lozenges). Participants will also receive referrals to various alcohol-related treatment options in the community.

Sponsors

H. Lee Moffitt Cancer Center and Research Institute
Lead SponsorOTHER
Florida Biomedical Research Program - James & Esther King
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* ≥18 years old * History of a cancer diagnosis at any point in lifetime * Smoked ≥1 cigarette/day in past month * At least one binge drinking episode in past month or exceeds weekly drinking limits * Motivated to quit smoking and modify alcohol use in next 30 days * Valid home address in Florida * English-speaking, reading, and writing ability

Exclusion criteria

* Pregnancy or lactation * Active psychotic disorder * History of severe alcohol withdrawal * Current use of tobacco cessation medication or other treatments to quit smoking * End-of-life or hospice care * Household member already enrolled

Design outcomes

Primary

MeasureTime frameDescription
Biochemically Confirmed 7-Day Point Prevalence Smoking Abstinence6 months post treatmentSelf-reported no combustible tobacco use in the past 7 days, verified with saliva cotinine \<10 ng/mL.
Percent Heavy Drinking Days (Past 4 Weeks)6 months post treatmentPercentage of days in the past 4 weeks meeting heavy drinking criteria (≥5 drinks for men; ≥4 drinks for women)

Countries

United States

Contacts

CONTACTSkye Dougan, MPH
Skye.Dougan@moffitt.org813-745-4376
CONTACTMarilyn Horta, PhD
Marilyn.Horta@moffitt.org813-745-3861
PRINCIPAL_INVESTIGATORChristine Vinci, PhD

Moffitt Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026